Compare WORX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WORX | BIAF |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.6M |
| IPO Year | 2016 | N/A |
| Metric | WORX | BIAF |
|---|---|---|
| Price | $0.12 | $1.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.7M | 226.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,989,599.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.16 |
| 52 Week High | $1.37 | $13.50 |
| Indicator | WORX | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 47.36 |
| Support Level | N/A | $0.90 |
| Resistance Level | $0.35 | $1.45 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 2.78 | 28.57 |
SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.